Individual Study / PLCO

Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Initiatives -
The main aim of the study was to determine in screenees ages 55-74 at entry whether screening with flexible sigmoidoscopy (60-cm sigmoidoscope) can reduce mortality from colorectal cancer, whether screening with chest X-ray can reduce mortality from lung cancer, whether screening men with digital rectal examination (DRE) plus serum prostate-specific antigen (PSA) can reduce mortality from prostate cancer, and whether screening women with CA125 and transvaginal ultrasound (TVU) can reduce mortality from ovarian cancer. Secondary objectives are to assess screening variables other than mortality for each of the interventions including sensitivity, specificity, and positive predictive value; to assess incidence, stage, and survival of cancer cases; and to investigate biologic and/ or prognostic characterizations of tumor tissue and biochemical products as intermediate endpoints.
Start Year
National Cancer Institute (NCI)
Supplementary Information
Visit PLCO


Investigators Contacts
  • Dr. Prof. Marc Bissonnette
    University of Chicago
  • Dr. Paul Pinsky
    National Cancer Institute


Study design
Clinical trial
Follow Up
In the intervention arm, the PSA and CA125 tests are performed at entry, then annually for 5 years. The DRE, TVU, and chest X-ray exams are performed at entry and then annually for 3 years. Sigmoidoscopy is performed at entry and then at the 5-year point. Participants in the control arm follow their usual medical care practices. Participants will be followed for at least 13 years from randomization to ascertain all cancers of the prostate, lung, colorectum, and ovary, as well as deaths from all causes.
Supplementary Information

Marker Paper

Gohagan JK, Prorok PC, Hayes RB, Kramer BS; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21(6 Suppl):251S-272S. doi:10.1016/s0197-2456(00)00097-0 Format:

PUBMED 11189683


Sources of Recruitment
  • Individuals

Number of participants

Number of participants
Number of participants with biosamples


Availability of data and biosamples


Availability of access information

On the study website :